Jasper Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Mar 5, 2024 and accepted by EDGAR at Mar 5, 2024, 21:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-01-01 to 2023-12-31 | $51.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$68.9m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$64.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$6.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$6.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 10,439,034 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$52.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-12-31 | $86.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $88.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $94.9m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $12.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $16.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $78.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-020114. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.